TAEST-1901

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameTAEST-1901
Drug Alias NameTAEST-1901
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionHLA class I histocompatibility antigen, A alpha chain modulatorsAlpha-fetoprotein inhibitors
TargetsHLA class I histocompatibility antigen, A alpha chainAlpha-fetoprotein
Therapy Area/IndicationsSolid tumoursLiver NeoplasmsStomach Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesXiangxue Life Science Technology (Guangdong) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCancer Hospital Of Chinese Academy Of Medical SciencesXiangxue Life Science Technology (Guangdong) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLiver NeoplasmsStomach Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A